<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="343266">
  <stage>Registered</stage>
  <submitdate>28/07/2011</submitdate>
  <approvaldate>28/07/2011</approvaldate>
  <actrnumber>ACTRN12611000794909</actrnumber>
  <trial_identification>
    <studytitle>The effect of intravenous sedation on the lower oesophageal sphincter:  A comparison between dexmedetomidine and remifentanil in healthy adult volunteers.</studytitle>
    <scientifictitle>The effect of intravenous sedation on the lower oesophageal sphincter:  A comparison between dexmedetomidine and remifentanil in healthy adult volunteers.</scientifictitle>
    <utrn>U1111-1123-2271</utrn>
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Aspiration Risk during sedation</healthcondition>
    <healthcondition>Reflux and sedation</healthcondition>
    <conditioncode>
      <conditioncode1>Anaesthesiology</conditioncode1>
      <conditioncode2>Anaesthetics</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Sedation of Healthy volunteers. Cross over study between 2 sedation medications: Remifentanil and Dexmedetomidine.
Remifentanil Sedation: Target-Controlled Infusion: 0.1, 0.2, 0.3 and 0.4 mcg/Kg/min. Duration: 20 minutes at each target concentration.
Period between cross-over: 1 week
Target controlled infusions will be administered consecutively in an ascending pattern (lower to higher concentrations)</interventions>
    <comparator>Dexmedetomidine Sedation. Target Controlled Infusions:0.1, 0.2, 0.4, 0.6 and 0.8 ng/ml.  Duration: 20 minutes at each target concentration
Target controlled infusions will be administered consecutively in an ascending pattern (lower to higher concentrations)</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Oesophageal motor activity as assessed by oesophageal manometry, using multi-lumen perfused catheters</outcome>
      <timepoint>continuous measurement at time of administration of sedating infusion.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>oesophageal motility and reflux will be assessed by oesophageal intraluminal electrical impedance, using 4 pairs of ring electrodes.</outcome>
      <timepoint>continuous measurement at time of administration of sedating infusion.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Oesophageal  pH will be monitored using an antimony pH electrode positioned 5cm above the proximal margin of the LOS</outcome>
      <timepoint>continuous measurement at time of administration of sedating infusion.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Patient reported alertness will be assessed by Visual Analogue Scale (VAS)</outcome>
      <timepoint>10 minutes after commencement of each target plasma concentration</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Observer Assessment of Alertness/Sedation Scale (OASS)</outcome>
      <timepoint>10 minutes after commencement of each target plasma concentration</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Patient's response to temperature (as a marker of analgesia) will be assessed by a Thermal Sensory Analyser (TSA)</outcome>
      <timepoint>15 minutes after commencement of each target plasma concentration</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pateints' quantitative EEG activity will be assessed by Bispectral index (BIS) measurement</outcome>
      <timepoint>continuous measurement at 5-minute intervals during administration of sedating infusion</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Healthy volunteers</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>55</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>(i)	Inability to give informed consent 
(ii)	Pregnancy or breast feeding 
(iii)	Previous gastrointestinal surgery (apart from appendicectomy) 
(iv)	medications known to affect gastrointestinal motility (erythromycin, metoclopramide and domperidone)  
(v)	Clinically diagnosed gastro-oesophageal reflux disease and on acid suppression therapy
(vi)	Current use of opiates or any sedatives
(vii)	History of cardiac disease
(viii)	History of lung disease
(ix)	Smoking 
(x)	Kidney disease 
(xi)	Liver disease 
(xii)	 diabetes
(xiii)	Known allergy to anaesthetic drugs or any reported difficulties during previous anaesthesia 
(xiv)	BMI &gt; 33</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Enrollment: Advertising
Allocation: Concealment performed by central randomisation by computer.</concealment>
    <sequence>Simple randomisation using a randomisation table created by computer software (i.e. computerised sequence generation).</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint>Safety</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>1/09/2011</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>16</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Dr Islam Elhalawani</primarysponsorname>
    <primarysponsoraddress>The Queen Elizabeth Hospital
Anaesthesia
28 WoodvilleRoad
Woodville West 
SA
5011</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>NHMRC</fundingname>
      <fundingaddress>National Health and Medical Research Council
Level 1
16 Marcus Clarke Street
Canberra ACT 2601</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The primary aim of this study is to assess the effect of sedation on lower oesophageal sphincter (LOS) function and to compare the effects of two types of sedating drugs, Remifentanil and Dexmedetomidine, on LOS function. This is performed to assess the risk of aspiration during sedation both in theatres as well as the intensive care unit.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>The Royal Adelaide Hospital Ethics Committee</ethicname>
      <ethicaddress>The Royal Adelaide Hospital
North Terrace 
Adelaide 
5000
SA</ethicaddress>
      <ethicapprovaldate>16/11/2010</ethicapprovaldate>
      <hrec>100824</hrec>
      <ethicsubmitdate>21/07/2010</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Islam Elhalawani</name>
      <address>The Queen Elizabeth Hospital 
Anaesthesia Department
28 Woodville Road 
Woodville West 
SA 5011</address>
      <phone>+618 8222 6000</phone>
      <fax />
      <email>elhalawani@me.com</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Islam Elhalawani</name>
      <address>The Queen Elizabeth Hospital 
Anaesthesia Department
28 Woodville Road 
Woodville West 
SA 5011</address>
      <phone>+618 8222 6000</phone>
      <fax />
      <email>elhalawani@me.com</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Islam Elhalawani</name>
      <address>The Queen Elizabeth Hospital 
Anaesthesia Department
28 Woodville Road 
Woodville West 
SA 5011</address>
      <phone>+618 8222 6000</phone>
      <fax />
      <email>elhalawani@me.com</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>